News

GoCART Coalition: EHA and EBMT Join Forces To Position Europe In The Lead Of The Global Cellular Therapy Field

The European Hematology Association (EHA) and the European Society of Blood and Marrow Transplantation (EBMT) announce a strategic partnership to empower Europe to become a global leader in the cellular therapy field for haematological diseases.

The two leading European societies in the field of haematology and stem cell transplantation join forces and bring their collective resources and expertise to the newly founded GoCART coalition.

Advancing the field of cell and gene-based therapies requires progress on multiple fronts, including creating a pre- and post-authorisation registry to monitor product safety and efficacy; harmonising data collection, centre qualification and educational requirements; overcoming barriers in regulations designed for more traditional pharmaceutical products, that affect preparation, administration and patient access to these novel therapies.

To address such a wide range of complex issues, there is a need for strong collaboration amongst all relevant stakeholders. The aim of the GoCART Coalition is to support patients‘ access to novel gene and cellular therapies manufactured from cells and tissues of hematopoietic origin, and to contribute to their health and well-being through innovation by multi-stakeholder collaboration on clinical data, standards of care, education and policy.

“This is historic, two large European organisations with a limited history of working together, have now joined forces,” commented Nicolaus Kröger, EBMT President. “With this example, we are sending a signal to other stakeholders of the possibilities to find common ground and achieve alignment. Only when we combine and leverage our individual strengths, can we move the field of cellular therapies forward.”

John Gribben, EHA President added: “We should avoid duplicating our efforts. What is more, we are not looking to be additive, we are looking to be synergistic so we can continue to build on and accelerate the excellent work that is already being done in Europe in the field of immunotherapy.

The first concrete activities underway of the GoCART Coalition include the development of a joint educational programme, a multi-stakeholder review of EBMT’s cellular therapy data collection form, and harmonisation of existing site qualification schemes to reduce inspection burden for hospitals.

Find more information on the GoCART Coalition HERE

 

Schaltfläche "Zurück zum Anfang"